Clinical trials: Generalised Anxiety Disorder
Generalized Anxiety Disorder
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
- Trial name
- NCT00616655
- Testing
- eszopiclone
- Where
- 57 sites in United States
- Volunteers
- 456 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anxiety Generalized
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects…
- Trial name
- NCT05407064
- Testing
- MM120
- Where
- 22 sites in United States
- Volunteers
- 198 people
- Sponsor
- Definium Therapeutics US, Inc.
Generalized Anxiety Disorder
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
- Trial name
- NCT06741228
- Testing
- DT120
- Where
- 34 sites in United States
- Volunteers
- 214 people
- Sponsor
- Definium Therapeutics US, Inc.
Anxiety Disorder Generalized
A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo- and active-controlled study to assess the efficacy and safety of CD-008-0045 in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT04598867
- Testing
- CD-008-0045, Afobazol
- Volunteers
- 200 people
- Sponsor
- ChemRar Research and Development Institute, LLC
Obsessive Compulsive Disorder (OCD), Bipolar Disorders
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
- Conditions
- Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
- Trial name
- NCT06823024
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Psyrin Inc.
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Generalized Anxiety Disorder
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
- Trial name
- NCT06809595
- Testing
- DT120
- Where
- 36 sites in United States, Czechia and 4 more
- Volunteers
- 245 people
- Sponsor
- Definium Therapeutics US, Inc.
Anxiety Disorders
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder
- Trial name
- NCT00374166
- Testing
- SSR149415, Paroxetine
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
- Trial name
- NCT00595231
- Testing
- SYN111
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Biotie Therapies Inc.
Generalized Anxiety Disorder
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult…
- Trial name
- NCT07786454
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disease
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.
- Trial name
- NCT00820794
- Testing
- Lithium, PD 0332334
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Anxiety Disorders
Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder
The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for individuals with generalized anxiety disorder.
- Trial name
- NCT03683472
- Testing
- Unwinding Anxiety Phone App
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- MindSciences, Inc.
Generalized Anxiety Disorder
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
- Trial name
- NCT00236054
- Testing
- Gabitril
- Where
- 19 sites in United States
- Volunteers
- 440 people
- Sponsor
- Cephalon
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- NCT01844115
- Testing
- Vilazodone
- Where
- 36 sites in United States
- Volunteers
- 415 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00731120
- Testing
- Vortioxetine
- Where
- 40 sites in United States
- Volunteers
- 457 people
- Sponsor
- Takeda
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in…
- Trial name
- AQUARIUS (NCT00266747)
- Testing
- SR58611A
- Where
- 7 sites in Argentina, Austria and 5 more
- Volunteers
- 366 people
- Sponsor
- Sanofi
General Anxiety Disorder
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00233675
- Testing
- GABITRIL (tiagabine hydrochloride; CEP-6671)
- Where
- 28 sites in United States
- Sponsor
- Cephalon
Anxiety Disorder
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control.
- Trial name
- LIBRA (NCT00252343)
- Testing
- SR58611A
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD).
- Trial name
- NCT00413010
- Testing
- pregabalin
- Where
- 68 sites in United States, Czechia and 6 more
- Volunteers
- 356 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.